[Duffy-blood-factor incompatibility during pregnancy (author's transl)]

Area of Science:

• Immunology
• Maternal-fetal medicine
• Blood group serology

Background:

• Routine prenatal screening for maternal antibodies is crucial for identifying potential risks to fetal well-being.
• The Duffy Blood Group System, specifically the Fya antigen, can elicit an immune response in sensitized individuals.
• Anti-Fya alloimmunization can lead to hemolytic disease of the fetus and newborn (HDFN).

Observation:

• A 25-year-old, second-time pregnant woman presented with anti-Fya antibodies.
• Spectroscopic examination of amniotic fluid was performed during the third trimester.
• Amniotic fluid spectrophotometry revealed values decreasing within Zone II, indicating a potential reduction in fetal hemolysis.

Findings:

• The presence of anti-Fya antibodies was confirmed in the maternal serum.
• Amniotic fluid analysis showed spectrophotometric values consistent with a less severe fetal condition.
• A mature newborn was delivered at 39 weeks gestation.
• The neonate did not require exchange transfusion immediately after birth, suggesting a favorable clinical outcome.

Implications:

• This case highlights the importance of vigilant antibody screening in pregnancy.
• Amniotic fluid spectrophotometry can aid in assessing the severity of fetal anemia due to anti-Fya.
• Early detection and monitoring may lead to successful outcomes in pregnancies complicated by anti-Fya alloimmunization.